Silence Therapeutics plc, a biotechnology firm headquartered in London, United Kingdom, is dedicated to the discovery and advancement of pioneering ribonucleic acid (RNA) therapeutics. Its research and development efforts span key areas such as blood disorders, cardiovascular health, and other uncommon and metabolic ailments. Central to the company's approach is its proprietary mRNAi GalNAc Oligonucleotide Discovery platform, meticulously crafted to precisely target specific disease-causing genes, predominantly within the liver. This mechanism involves creating short interfering RNA (siRNA) molecules that activate the body's intrinsic RNA interference pathway, effectively breaking down messenger RNA (mRNA) sequences responsible for producing particular disease-associated proteins inside cells. Silence Therapeutics is actively developing a pipeline of therapeutic candidates. This includes SLN360, currently in Phase I clinical trials for the treatment of cardiovascular disease characterized by elevated lipoprotein levels. Furthermore, SLN124 is progressing through Phase I clinical trials for both non-transfusion dependent thalassemia and myelodysplastic syndrome, with ongoing development also focused on polycythemia vera. The company has forged strategic partnerships to broaden its reach and capabilities. It collaborates with AstraZeneca PLC to identify, develop, and commercialize small interfering RNA therapeutics addressing cardiovascular, renal, metabolic, and respiratory conditions. Another alliance is with Mallinckrodt Pharma IP Trading DAC, centered on developing and marketing RNAi drug targets designed to inhibit the complement cascade in various complement-mediated disorders. Additionally, Silence Therapeutics is working with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three confidential targets, utilizing its mRNAi GOLD platform. The organization, which operated as SR Pharma plc until its rebranding in May 2007, continues its mission under the name Silence Therapeutics plc.